

22 June 2022

Novartis Pharma AG
Basel, Switzerland
CH-4002

Reference: EudraCT 2020-003906-29 Novartis Protocol ID CLCZ696G2301E1.

A multicenter study to evaluate the long-term safety and tolerability of open-label LCZ696 in patients with acute myocardial infarction who previously participated in CLCZ696G2301 (PARADISE-MI)

Trial 2020-003906-29 was cancelled with no patient enrollment and as such, no results will be reported.